title: Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
abstract: Studies were directed to characterization of the anaemia of renal failure of 11 patients on haemodialysis and determination of the way in which it is corrected by human erythropoietin derived from recombinant DNA expressed in Chinese hamster ovary cells (r-HuEPO) administered intravenously. Erythrokinetics before treatment showed that total red cell mass was below normal and that both erythron transferrin uptake and red cell survival were modestly reduced; treatment increased both total red cell mass and erythron transferrin uptake but did not change red cell survival in previously untransfused patients. When BFU-e and CFU-e from patient bone marrow were cultured in autologous serum we found no evidence for inhibitors of erythroid progenitor maturation in patient serum compared with normal. Erythroid expansion in response to r-HuEPO was not limited by the availability of iron, iron requirements for new red cell formation being met from stores (if adequate) or from oral iron supplements. In pharmacokinetic studies the plasma clearance of r-HuEPO could be expressed by a three-parameter exponential curve with T1/2 range of 2.3 to 7.3 h. T1/2 after the first dose of r-HuEPO was not significantly different from that after 14 to 54 weeks treatment when the erythron had expanded to a new steady state. Erythron transferrin uptake before treatment was related to endogenous production of erythropoietin estimated from the plasma clearance of the first dose of r-HuEPO administered intravenously. This finding suggested that the availability of erythropoietin was the main factor limiting expansion of the erythron. This conclusion was supported by the continuity of the relationship during the response to treatment.
authors.affiliation: Section of Haematology, Clinical Research Centre, Harrow, Middlesex.
authors.forename: P M
authors.initials: PM
authors.lastname: Cotes
authors.forename: M J
authors.initials: MJ
authors.lastname: Pippard
authors.forename: C D
authors.initials: CD
authors.lastname: Reid
authors.forename: C G
authors.initials: CG
authors.lastname: Winearls
authors.forename: D O
authors.initials: DO
authors.lastname: Oliver
authors.forename: J P
authors.initials: JP
authors.lastname: Royston
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000150:complications / Q000209:etiology / Q000628:therapy*; D015672:Erythroid Precursor Cells / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010953:Plasma Volume; D006435:Renal Dialysis; D014168:Transferrin / Q000378:metabolism
chemical_list: D014168:Transferrin; D004921:Erythropoietin